- Title
- BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers
- Creators
- Jae-Weon Kim - Seoul National University HospitalDomenica Lorusso - Mylan (Switzerland)Bradley Monk - Florida Cancer Specialists and Research Institute, West Palm Beach, FL, United StatesJeong-Yeol Park - University of UlsanNicoletta Colombo - Mylan (Switzerland)Carolyn Muller - University of New MexicoLaurence Gladieff - Oncopole Claudius Regaud IUCT-Oncopole, Toulouse, FranceAlexander Olawaiye - University of PittsburghToon Van Gorp - University Hospital Leuven, KU Leuven, Leuven, BelgiumAna Santaballa Bertrán - Hospital La Fe Valencia, Valencia, SpainRicardo Felberbaum - Hospital Kempten, Kempten, GermanyLubomir Bodnar - University of SiedlceLorena Fariñas Madrid - Hebron UniversityPremal Thaker - Washington University in St. LouisHristina Pashova - Menlo SchoolBhagyashree Yadav - Menlo SchoolSachin Pai - Menlo SchoolBrian Slomovitz - Mount Sinai Medical CenterAdrianne Mallen - MN Oncology, Edina, MN, United States
- Publication Details
- Gynecologic oncology, Vol.208, pp.S107-S107
- Publisher
- Elsevier Inc
- Identifiers
- 991006271903502656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers
Gynecologic oncology, Vol.208, pp.S107-S107
05/2026
Metrics
1 Record Views